Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Johnson & Johnson has unveiled new data from Phase 3 trials for icotrokinra (JNJ-2113), an investigational oral peptide ...
4d
GlobalData on MSNJ&J and Protagonist’s icotrokinra scores in Phase IIb UC studyGlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results